EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

Nicola Squillace iD, Elena Ricci, Paolo Maggi, Lucia Taramasso, Barbara Menzaghi, Giuseppe Vittorio De Socio, Stefania Piconi iD, Benedetto Maurizio Celesia iD, Giancarlo Orofino, Eleonora Sarchi, Giovanni Francesco Pellicanò iD, Filomena Simeone und 11 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0289132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Nicola Squillace und 22 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Integrase strand transfer inhibitors (INSTI) are one of the most prescribed drug classes for the treatment of HIV infection worldwide. Emtricitabine/Tenofovir Alafenamide/ Bictegravir (FTC/TAF/BIC) has been evaluated in randomized clinical trials; few studies have verified tolerability and safety in clinical practice. Our aim was to investigate the metabolic and hepatic safety in a real-life setting of FTC/TAF/BIC. Materials and methods Consecutive people living with HIV infection (PLWH) enrolled in the SCOLTA project, switching to or initiating their first antiretroviral treatment with FTC/TAF/BIC were included. PLWH with HBV co-infection were excluded. Metabolic and hepatic variables were collected at T0 and T1, were defined as baseline and 6-month follow-up respectively, and their modifications were analysed using the paired t-test and the analysis of variance.

Results

Five hundred and thirty-nine PLWH with at least one follow-up visit were included in the analysis. Mean age was 48 years (±12.1), 74% were male, 16.1% were naïve to antiretrovirals (ART). At T1, ART-experienced PLWH showed a significant reduction of total cholesterol (TC) and triglycerides, and a slight increase in blood glucose (BG) and ALT. On the contrary, in ART-naïve PLWH blood lipids significantly increased, although with an unaffected TC/high density lipoprotein (HDL)-c ratio, while alanine aminotransferase (ALT) decreased significantly, mainly in those with altered baseline level. The treatment interruptions were 45 (8.4%) over the whole observation period, 13 (2.4%) due to AEs. The most frequent AEs were related to the central nervous system (6 events of depression, insomnia, headache, agitation) and 3 PLWH discontinued the regimen because of grade 1–2 weight gain.

Conclusions

In ART-experienced PLWH switching to FTC/TAF/BIC a significant improvement of lipid profile occurred but with significant BG and ALT variation without clinical relevance. In ART-naïve PLWH, blood lipids increased even though lipid profile did not worsen, and a trend towards normalization of liver enzymes was suggested. FTC/TAF/BIC is well tolerated in the real life setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsMaleHumansMiddle AgedFemaleEmtricitabineAlanineHeterocyclic Compounds, 3-RingPyridonesAnti-Retroviral AgentsLipoproteins, HDLTenofovirAmidesPiperazinesAdenine

Substanzen

Anti-HIV AgentsEmtricitabineAlanineHeterocyclic Compounds, 3-RingPyridonesAnti-Retroviral AgentsLipoproteins, HDLtenofovir alafenamideTenofovirbictegravir

Autor:innen und Institutionen

  • Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Fondazione ASIA Onlus, Buccinasco (MI), Italy.
  • Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.
  • Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
  • Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio (VA), Italy.
  • Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy.

ORCID-Profile: Nicola Squillace, Stefania Piconi, Benedetto Maurizio Celesia, Giovanni Francesco Pellicanò

Förderung

  • Gilead Sciences

Zitieren

APA

Squillace, N., Ricci, E., Maggi, P., Taramasso, L., Menzaghi, B., De Socio, G. V., Piconi, S., Maurizio Celesia, B., Orofino, G., Sarchi, E., Pellicanò, G. F., Simeone, F., Valsecchi, L., Bandera, A., Cenderello, G., Attala, L., Angioni, G., Falasca, K., Cascio, A., …, & CISAI Study Group (2023). Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir. PLOS ONE. https://doi.org/10.1371/journal.pone.0289132

Vancouver

Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio GV, et al. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir. PLOS ONE. 2023. doi:10.1371/journal.pone.0289132

BibTeX
@article{Squillace2023,
  author = {Squillace, Nicola and Ricci, Elena and Maggi, Paolo and Taramasso, Lucia and Menzaghi, Barbara and De Socio, Giuseppe Vittorio and Piconi, Stefania and Maurizio Celesia, Benedetto and Orofino, Giancarlo and Sarchi, Eleonora and Pellicanò, Giovanni Francesco and Simeone, Filomena and Valsecchi, Laura and Bandera, Alessandra and Cenderello, Giovanni and Attala, Letizia and Angioni, Goffredo and Falasca, Katia and Cascio, Antonio and Bargiacchi, Olivia and Di Biagio, Antonio and Bonfanti, Paolo and CISAI Study Group, CISAI Study Group},
  title = {Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0289132}
}
Kostenlos starten →